price
NASDAQ · PRQR
ProQR Therapeutics N.V.
Healthcare · Biotechnology
$1.84
Down-$0.02 (-1.08%)
Updated Sep 16, 2026, 8:47 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 249.67M
- P/E ratio
- -5.37
- Dividend yield
- 0.00%
- 52-week range
- $1.35 – $2.46
- Volume
- 721.64K
- Avg. volume
- 502.75K
Price performance
PRQR price history
1M range · 20 trading sessions · Daily adjusted prices
PRQR closed at $1.84 after 20 trading sessions, down 14.42% for the selected period.
- Last close
- $1.84
- Period change
- -14.42%
- Period low
- $1.84
- Period high
- $2.43
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $1.89 | $1.89 | $1.79 | $1.84 | 721.64K |
| Sep 14, 2026 | $1.88 | $1.88 | $1.8114 | $1.86 | 630.05K |
| Sep 11, 2026 | $1.97 | $1.98 | $1.85 | $1.86 | 581.23K |
| Sep 10, 2026 | $1.96 | $1.96 | $1.915 | $1.94 | 479.99K |
| Sep 9, 2026 | $2.05 | $2.125 | $1.97 | $1.99 | 958.27K |
| Sep 8, 2026 | $2.07 | $2.11 | $2.02 | $2.05 | 449.2K |
| Sep 4, 2026 | $2.06 | $2.11 | $2.06 | $2.07 | 368.46K |
| Sep 3, 2026 | $2.16 | $2.20 | $2.07 | $2.09 | 697.4K |
| Sep 2, 2026 | $2.15 | $2.2181 | $2.12 | $2.15 | 389.55K |
| Sep 1, 2026 | $2.13 | $2.15 | $2.07 | $2.12 | 569.34K |
| Aug 31, 2026 | $2.29 | $2.29 | $2.12 | $2.13 | 943.52K |
| Aug 28, 2026 | $2.31 | $2.35 | $2.275 | $2.29 | 459.37K |
| Aug 27, 2026 | $2.29 | $2.35 | $2.24 | $2.32 | 1.29M |
| Aug 26, 2026 | $2.38 | $2.40 | $2.275 | $2.35 | 700.03K |
| Aug 25, 2026 | $2.42 | $2.425 | $2.235 | $2.38 | 2.18M |
| Aug 24, 2026 | $2.35 | $2.46 | $2.26 | $2.43 | 1.06M |
| Aug 21, 2026 | $2.28 | $2.37 | $2.26 | $2.34 | 725.82K |
| Aug 20, 2026 | $2.35 | $2.445 | $2.1403 | $2.27 | 2.67M |
| Aug 19, 2026 | $2.18 | $2.25 | $2.1201 | $2.22 | 981.95K |
| Aug 18, 2026 | $1.93 | $2.16 | $1.89 | $2.15 | 1.56M |
Latest PRQR news
The latest Smart Investors Daily articles mentioning PRQR.
Stock researchCompany · Overview
PRQR research
Overview
Company profile and research snapshot.
Company profile
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $3.63
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | B of A Securities | Buy | — |
| Jun 29, 2026 | Evercore ISI Group | Outperform | — |
| Jun 26, 2026 | Jones Trading | Buy | — |
| Jun 26, 2026 | Chardan Capital | Buy | — |
| Apr 9, 2026 | Chardan Capital | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.